The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia.
M. Juckett
No relevant relationships to disclose
B. LaPlant
No relevant relationships to disclose
P. J. Flynn
No relevant relationships to disclose
A. Jumonville
No relevant relationships to disclose
A. Moreno-Aspitia
No relevant relationships to disclose
C. Erlichman
No relevant relationships to disclose